CN Patent

CN120265773A — 靶向c3的小干扰rna及其用途

Assigned to Saint Germain Biotech Inc · Expires 2025-07-04 · 1y expired

What this patent protects

本公开内容涉及包含靶向人类补体C3mRNA的双链体区域的分离的寡核苷酸，和包含其的递送系统、药盒和组合物，以及使用其用于抑制或下调C3基因表达的方法。

USPTO Abstract

本公开内容涉及包含靶向人类补体C3mRNA的双链体区域的分离的寡核苷酸，和包含其的递送系统、药盒和组合物，以及使用其用于抑制或下调C3基因表达的方法。

Drugs covered by this patent

vutrisiran-sodium (VUTRISIRAN SODIUM)

Patent Metadata

Patent number: CN120265773A
Jurisdiction: CN
Classification: —
Expires: 2025-07-04
Drug substance claim: No
Drug product claim: No
Assignee: Saint Germain Biotech Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.